Nifty
Sensex
:
:
10813.45
36737.69
107.70 (1.01%)
408.68 (1.12%)

Chemicals

Rating :
69/99  (View)

BSE: 530019 | NSE: JUBILANT

709.30
6.80 (0.97%)
09-Jul-2020 | 3:56PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  716.00
  •  729.00
  •  707.60
  •  702.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  631955
  •  4482.46
  •  729.00
  •  234.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 11,196.67
  • 12.47
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 14,666.69
  • 0.64%
  • 2.00

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.68%
  • 3.26%
  • 13.48%
  • FII
  • DII
  • Others
  • 27.91%
  • 1.40%
  • 3.27%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.16
  • 9.35
  • 15.84

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.84
  • 19.91
  • 5.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.15
  • -6.37
  • -0.07

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.03
  • 16.79
  • 15.20

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.88
  • 2.42
  • 2.33

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.28
  • 9.05
  • 8.50

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
2,391
2,386
0%
2,315
2,377
-3%
2,266
2,269
0%
2,182
2,079
5%
Expenses
1,855
2,028
-9%
1,808
1,884
-4%
1,797
1,819
-1%
1,747
1,641
6%
EBITDA
537
358
50%
507
493
3%
468
450
4%
435
438
-1%
EBIDTM
22%
15%
22%
21%
21%
20%
20%
21%
Other Income
19
-7
-
6
29
-79%
12
4
220%
10
9
2%
Interest
71
62
16%
72
53
36%
72
54
32%
73
51
43%
Depreciation
129
95
36%
113
98
15%
117
89
31%
103
88
17%
PBT
356
-40
-
293
356
-18%
292
302
-3%
269
286
-6%
Tax
95
61
57%
90
88
2%
43
92
-53%
84
86
-2%
PAT
260
-101
-
203
268
-24%
249
210
19%
185
200
-8%
PATM
11%
-4%
9%
11%
11%
9%
8%
10%
EPS
16.35
-6.32
-
12.77
16.79
-24%
15.66
13.17
19%
11.61
12.58
-8%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
9,154
9,111
7,518
5,861
5,749
5,826
5,803
5,166
4,303
3,446
3,791
Net Sales Growth
0%
21%
28%
2%
-1%
0%
12%
20%
25%
-9%
 
Cost Of Goods Sold
3,141
3,522
2,863
2,003
2,116
2,663
2,438
2,063
1,619
1,340
1,471
Gross Profit
6,014
5,589
4,655
3,859
3,633
3,163
3,365
3,103
2,684
2,106
2,320
GP Margin
66%
61%
62%
66%
63%
54%
58%
60%
62%
61%
61%
Total Expenditure
7,207
7,372
5,999
4,516
4,502
5,125
4,782
4,098
3,413
2,881
3,111
Power & Fuel Cost
-
466
425
334
367
393
390
357
287
224
220
% Of Sales
-
5%
6%
6%
6%
7%
7%
7%
7%
6%
6%
Employee Cost
-
1,926
1,556
1,231
1,125
1,090
1,105
963
836
719
735
% Of Sales
-
21%
21%
21%
20%
19%
19%
19%
19%
21%
19%
Manufacturing Exp.
-
552
486
429
436
432
405
360
330
285
316
% Of Sales
-
6%
6%
7%
8%
7%
7%
7%
8%
8%
8%
General & Admin Exp.
-
541
355
281
256
302
264
208
201
196
197
% Of Sales
-
6%
5%
5%
4%
5%
5%
4%
5%
6%
5%
Selling & Distn. Exp.
-
268
248
186
136
204
160
123
112
91
126
% Of Sales
-
3%
3%
3%
2%
4%
3%
2%
3%
3%
3%
Miscellaneous Exp.
-
97
68
53
66
40
20
24
28
27
126
% Of Sales
-
1%
1%
1%
1%
1%
0%
0%
1%
1%
1%
EBITDA
1,947
1,739
1,518
1,345
1,247
702
1,021
1,068
890
565
680
EBITDA Margin
21%
19%
20%
23%
22%
12%
18%
21%
21%
16%
18%
Other Income
47
36
40
25
13
42
19
30
31
17
118
Interest
287
220
284
341
371
368
337
311
238
120
156
Depreciation
462
371
415
291
347
288
281
254
221
180
125
PBT
1,211
1,184
859
738
542
88
422
533
463
282
518
Tax
312
327
225
163
155
80
70
152
68
13
96
Tax Rate
26%
36%
26%
22%
29%
200%
34%
45%
60%
6%
19%
PAT
898
574
643
576
392
-58
109
153
15
230
421
PAT before Minority Interest
898
577
634
575
387
-40
138
189
46
227
422
Minority Interest
0
-3
8
1
5
-18
-29
-36
-31
2
0
PAT Margin
10%
6%
9%
10%
7%
-1%
2%
3%
0%
7%
11%
PAT Growth
56%
-11%
12%
47%
778%
-153%
-29%
949%
-94%
-45%
 
EPS
56.39
36.06
40.35
36.14
24.60
-3.63
6.84
9.59
0.91
14.42
26.46

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
4,809
4,087
3,436
2,966
2,454
2,627
2,476
2,257
2,172
2,201
Share Capital
16
16
16
16
16
15
16
16
16
16
Total Reserves
4,793
4,071
3,420
2,951
2,438
2,611
2,460
2,241
2,156
2,185
Non-Current Liabilities
4,420
3,417
3,826
3,347
4,036
2,185
3,005
3,224
3,048
3,365
Secured Loans
812
730
1,582
2,620
3,316
1,717
1,709
2,839
2,436
2,161
Unsecured Loans
3,431
2,318
1,923
393
375
0
760
0
401
1,012
Long Term Provisions
114
107
81
70
67
220
238
170
40
0
Current Liabilities
2,090
2,005
1,684
2,464
2,129
3,894
2,778
2,213
2,270
1,220
Trade Payables
1,020
1,136
749
612
721
718
647
837
517
689
Other Current Liabilities
474
506
573
951
793
1,731
898
500
466
65
Short Term Borrowings
500
245
256
749
517
1,188
1,131
767
883
0
Short Term Provisions
96
118
106
152
97
257
102
109
403
467
Total Liabilities
11,319
9,457
8,899
8,740
8,619
8,864
8,371
7,763
7,532
6,825
Net Block
5,648
5,401
5,107
5,104
4,911
5,099
4,967
4,460
3,991
3,819
Gross Block
6,906
6,289
5,672
5,391
7,362
7,331
6,870
6,084
5,163
4,845
Accumulated Depreciation
1,257
888
566
286
2,451
2,232
1,903
1,624
1,172
1,026
Non Current Assets
6,734
6,267
5,951
5,864
5,904
5,936
5,810
5,466
4,940
4,357
Capital Work in Progress
901
671
684
611
597
472
437
686
667
506
Non Current Investment
115
124
103
85
40
34
26
19
33
33
Long Term Loans & Adv.
69
72
56
63
327
328
379
300
249
0
Other Non Current Assets
1
1
1
1
30
2
0
1
1
0
Current Assets
4,585
3,190
2,948
2,875
2,715
2,928
2,561
2,297
2,592
2,455
Current Investments
0
0
0
0
0
0
0
0
0
224
Inventories
1,417
1,391
1,220
1,203
1,235
1,341
1,116
1,020
691
691
Sundry Debtors
1,272
1,131
1,005
950
819
806
709
653
520
519
Cash & Bank
1,370
249
460
345
394
480
356
267
1,045
504
Other Current Assets
525
373
226
244
266
301
380
358
335
518
Short Term Loans & Adv.
40
46
37
133
145
136
182
257
218
498
Net Current Assets
2,495
1,185
1,264
411
585
-966
-217
85
322
1,235
Total Assets
11,319
9,457
8,899
8,740
8,619
8,864
8,371
7,763
7,532
6,825

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,122
1,303
1,268
1,099
783
772
970
707
390
710
PBT
904
859
738
542
40
207
341
114
241
518
Adjustment
862
688
638
738
726
757
752
795
318
189
Changes in Working Capital
-301
14
37
-133
96
-111
-4
-137
-84
63
Cash after chg. in Working capital
1,465
1,561
1,412
1,147
863
853
1,089
773
475
770
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-343
-258
-144
-48
-79
-81
-120
-65
-85
-61
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-1,012
-618
-450
-313
-343
-174
-500
-594
-352
-280
Net Fixed Assets
-306
-148
-115
786
1,162
-167
-286
-434
-275
-129
Net Investments
-58
3
0
57
240
-28
-19
-96
5
-160
Others
-649
-473
-335
-1,155
-1,746
20
-195
-64
-82
9
Cash from Financing Activity
657
-901
-686
-843
-503
-414
-450
-889
608
-298
Net Cash Inflow / Outflow
767
-216
132
-56
-63
183
20
-776
646
132
Opening Cash & Equivalents
244
456
339
392
473
280
263
1,041
498
382
Closing Cash & Equivalent
1,005
244
456
339
392
473
280
263
1,041
505

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
302
262
221
191
154
170
155
142
136
138
ROA
6%
7%
7%
4%
0%
2%
2%
1%
3%
6%
ROE
13%
17%
18%
14%
-2%
5%
8%
2%
10%
24%
ROCE
13%
15%
14%
12%
6%
8%
10%
6%
6%
13%
Fixed Asset Turnover
1.38
1.26
1.09
0.92
0.81
0.84
0.82
0.78
0.70
0.82
Receivable days
48
52
59
55
50
47
47
49
54
48
Inventory Days
56
63
74
76
79
76
74
71
72
61
Payable days
55
57
55
53
52
51
45
39
51
58
Cash Conversion Cycle
49
58
78
77
76
71
75
81
74
50
Total Debt/Equity
1.01
0.85
1.18
1.51
1.95
1.67
1.71
1.69
1.81
1.45
Interest Cover
5
4
3
2
1
2
2
1
3
4

News Update


  • Jubilant Life Sciences raises Rs 50 crore via Commercial Papers
    19th Jun 2020, 14:18 PM

    Date of maturity of the said Commercial Papers is August 18, 2020

    Read More
  • Jubilant Life Sciences raises Rs 50 crore via Commercial Papers
    13th Jun 2020, 13:23 PM

    Date of maturity of the said Commercial Papers is September 9, 2020

    Read More
  • Jubilant Life Sciences’ arm enters into licensing agreement with Gilead Sciences
    13th May 2020, 09:13 AM

    Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production

    Read More
  • Jubilant Life Sciences’ arm gets EIR from USFDA for Solid Dosage facility at Salisbury
    1st Apr 2020, 09:57 AM

    With the receipt of the EIR, the inspection stands successfully closed

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.